All In Biotech

Drug Trial Radar · NCT05099133

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

A Phase 1, Single-center, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Nov 3, 2021

Primary completion

Jun 28, 2022

Study completion Jun 28, 2022

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Oct 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial will investigate the pharmacokinetics, immunogenicity, safety, and tolerability of LEO 138559 in healthy Japanese subjects. The trial consists of a screening period of up to 4 weeks, a single treatment with either LEO 138559 or placebo, and 8 follow-up visits to Day 85. A total of 24 healthy subjects will be enrolled in 3 dose groups (n=8 per dose group) and randomized to either LEO 138559 or placebo in a ratio of 6:2.

Conditions

  • Atopic Dermatitis

Interventions

  • LEO 138559Drug

    LEO 138559 is an antibody given by injection just under the skin.

  • LEO 138559 PlaceboDrug

    LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-last: the area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentrationTime frame: From Day 1 to Day 85
  2. AUC0-inf: area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite timeTime frame: From Day 1 to Day 85
  3. Cmax: maximum serum LEO 138559 concentrationTime frame: From Day 1 to Day 85
  4. tmax: time of maximum serum LEO 138559 concentrationTime frame: From Day 1 to Day 85
  5. t½: terminal elimination half-lifeTime frame: From Day 1 to Day 85
  6. CL/F: apparent total body clearanceTime frame: From Day 1 to Day 85
  7. Vz/F: apparent volume of distributionTime frame: From Day 1 to Day 85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • LEO Investigational Site

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.